Rein Therapeutics Inc
RNTX1.140USD
+0.030+2.70%
Market hours （ET）Quotes delayed by 15 min
25.09MMarket Cap
LossP/E TTM
More Details of Rein Therapeutics Inc Company
Rein Therapeutics, Inc., formerly Aileron Therapeutics, Inc., is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. The Company's lead product candidate, LTI-03 (idiopathic pulmonary fibrosis), is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Its second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the United States and European Union and Fast Track Designation in the United States. Its pipeline also includes LTI-05 (cystic fibrosis).
Company Info
Ticker SymbolRNTX
Company nameRein Therapeutics Inc
IPO dateJun 29, 2017
CEODr. Brian Windsor, Ph.D.
Number of employees11
Security typeOrdinary Share
Fiscal year-endJun 29
Address12407 N. Mopac Expy.
CityAUSTIN
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code78758
Phone17378021989
Websitehttps://www.reintx.com/
Ticker SymbolRNTX
IPO dateJun 29, 2017
CEODr. Brian Windsor, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Manuel C. Alves Aivado, M.D., Ph.D.
Dr. Manuel C. Alves Aivado, M.D., Ph.D.
Director
Director
--
--
Mr. Josef H. Von Rickenbach
Mr. Josef H. Von Rickenbach
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Brian Windsor, Ph.D.
Dr. Brian Windsor, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Timothy M. (Tim) Cunningham, CPA
Mr. Timothy M. (Tim) Cunningham, CPA
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. Reinhard J. Ambros, Ph.D.
Dr. Reinhard J. Ambros, Ph.D.
Independent Director
Independent Director
--
--
Mr. William Carl (Bill) Fairey, Jr.
Mr. William Carl (Bill) Fairey, Jr.
Independent Director
Independent Director
--
--
Mr. Alan A. Musso, CPA
Mr. Alan A. Musso, CPA
Independent Director
Independent Director
--
--
Mr. Alan A. Musso, CPA
Mr. Alan A. Musso, CPA
Independent Director
Independent Director
--
--
Mr. William Carl (Bill) Fairey, Jr.
Mr. William Carl (Bill) Fairey, Jr.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Manuel C. Alves Aivado, M.D., Ph.D.
Dr. Manuel C. Alves Aivado, M.D., Ph.D.
Director
Director
--
--
Mr. Josef H. Von Rickenbach
Mr. Josef H. Von Rickenbach
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Brian Windsor, Ph.D.
Dr. Brian Windsor, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Timothy M. (Tim) Cunningham, CPA
Mr. Timothy M. (Tim) Cunningham, CPA
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. Reinhard J. Ambros, Ph.D.
Dr. Reinhard J. Ambros, Ph.D.
Independent Director
Independent Director
--
--
Mr. William Carl (Bill) Fairey, Jr.
Mr. William Carl (Bill) Fairey, Jr.
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q1
FY2024
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2022
No Data
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Jul 19
Updated: Sat, Jul 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Bios Equity Partners, LP.
7.34%
The Vanguard Group, Inc.
3.11%
University of Texas Investment Management Company
2.22%
Prosight Capital
1.87%
Cable Car Capital LLC
1.82%
Other
83.65%
Shareholders
Shareholders
Proportion
Bios Equity Partners, LP.
7.34%
The Vanguard Group, Inc.
3.11%
University of Texas Investment Management Company
2.22%
Prosight Capital
1.87%
Cable Car Capital LLC
1.82%
Other
83.65%
Shareholder Types
Shareholders
Proportion
Venture Capital
7.63%
Investment Advisor
5.90%
Hedge Fund
4.76%
Investment Advisor/Hedge Fund
3.54%
Endowment Fund
2.31%
Research Firm
0.37%
Individual Investor
0.09%
Pension Fund
0.07%
Other
75.33%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
66
5.46M
23.71%
-2.61M
2025Q1
68
6.05M
27.36%
-2.07M
2024Q4
62
5.71M
26.36%
-2.11M
2024Q3
68
6.75M
31.73%
-1.30M
2024Q2
70
7.04M
33.12%
+1.08M
2024Q1
72
3.75M
76.83%
+1.75M
2023Q4
68
1.31M
26.94%
-611.73K
2023Q3
73
1.46M
32.12%
-497.50K
2023Q2
81
1.44M
31.62%
-549.81K
2023Q1
85
1.46M
32.23%
-613.59K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Bios Equity Partners, LP.
1.69M
7.63%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
716.79K
3.24%
+291.79K
+68.66%
Mar 31, 2025
University of Texas Investment Management Company
511.61K
2.31%
-105.51K
-17.10%
Mar 31, 2025
Prosight Capital
430.00K
1.94%
+25.02K
+6.18%
Mar 31, 2025
Cable Car Capital LLC
420.00K
1.9%
--
--
Mar 31, 2025
Voss Capital LLC
374.93K
1.69%
-615.79K
-62.16%
May 14, 2025
Sigma Planning Corporation
305.18K
1.38%
+68.97K
+29.20%
Mar 31, 2025
Geode Capital Management, L.L.C.
246.10K
1.11%
+4.66K
+1.93%
Mar 31, 2025
Senvest Management, LLC
230.90K
1.04%
--
--
Mar 31, 2025
Gagnon Securities LLC
71.75K
0.32%
--
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0.01%
Fidelity Nasdaq Composite Index ETF
0%
iShares Micro-Cap ETF
Proportion0.01%
Fidelity Nasdaq Composite Index ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Nov 10, 2022
Merger
20<1
Nov 10, 2022
Merger
20<1
Nov 10, 2022
Merger
20<1
Nov 10, 2022
Merger
20<1
Date
Type
Ratio
Nov 10, 2022
Merger
20<1
Nov 10, 2022
Merger
20<1
Nov 10, 2022
Merger
20<1
Nov 10, 2022
Merger
20<1
